Technical Analysis for BGNE - BeiGene, Ltd.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Down | Down | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| MACD Bullish Signal Line Cross | Bullish | 0.00% | |
| Multiple of Ten Bullish | Other | 0.00% | |
| Outside Day | Range Expansion | 0.00% | |
| Wide Bands | Range Expansion | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Narrow Range Bar | Range Contraction | 4.29% | |
| NR7 | Range Contraction | 4.29% | |
| Inside Day | Range Contraction | 4.29% | |
| Wide Bands | Range Expansion | 4.29% | |
| Multiple of Ten Bullish | Other | 4.75% |
Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App
| Alert | Time |
|---|---|
| 10 DMA Support | 2 days ago |
| Outside Day | 2 days ago |
| Fell Below Previous Day's Low | 2 days ago |
| Down 1% | 2 days ago |
| Reversed from Up | 2 days ago |
Get a Trading Sidekick!
- Earnings date: 09/27/2019
BeiGene, Ltd. Description
BeiGene, Ltd., a clinical-stage biopharmaceutical company, discovers and develops various oncology drugs in the People's Republic of China. The company's clinical stage drug candidates include BGB-3111, a small molecule BTK inhibitor for the treatment of various lymphomas; BGB-283, a small molecule RAF dimer inhibitor to treat cancers with aberrations in the mitogen-activated protein kinase pathway, including BRAF mutations and KRAS/NRAS gene mutations; BGB-290, an inhibitor of PARP1 and PARP2 for the treatment of homologous recombination deficient cancers; and BGB-A317, a humanized monoclonal antibody for solid-organ and blood-borne cancers. Its preclinical programs comprise a PD-L1 monoclonal antibody, an additional RAF dimer inhibitor, a TIM-3 cell surface protein monoclonal antibody, and a BTK inhibitor for non-oncology indications. The company was founded in 2010 and is based in Camana Bay, Cayman Islands.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Monoclonal Antibody Lymphoma Monoclonal Antibodies Oncogenes Protein Kinase Kras Bruton's Tyrosine Kinase Ras Subfamily Recombination Rp1
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 426.56 |
| 52 Week Low | 120.0 |
| Average Volume | 342,252 |
| 200-Day Moving Average | 267.11 |
| 50-Day Moving Average | 170.46 |
| 20-Day Moving Average | 146.13 |
| 10-Day Moving Average | 133.12 |
| Average True Range | 12.32 |
| RSI | 41.86 |
| ADX | 28.62 |
| +DI | 18.65 |
| -DI | 31.44 |
| Chandelier Exit (Long, 3 ATRs) | 141.21 |
| Chandelier Exit (Short, 3 ATRs) | 156.95 |
| Upper Bollinger Bands | 174.43 |
| Lower Bollinger Band | 117.83 |
| Percent B (%b) | 0.34 |
| BandWidth | 38.73 |
| MACD Line | -12.33 |
| MACD Signal Line | -12.70 |
| MACD Histogram | 0.3718 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 152.54 | ||||
| Resistance 3 (R3) | 151.56 | 145.50 | 150.00 | ||
| Resistance 2 (R2) | 145.50 | 141.63 | 146.00 | 149.16 | |
| Resistance 1 (R1) | 141.41 | 139.23 | 138.39 | 142.39 | 148.31 |
| Pivot Point | 135.36 | 135.36 | 133.84 | 135.85 | 135.36 |
| Support 1 (S1) | 131.27 | 131.48 | 128.24 | 132.25 | 126.33 |
| Support 2 (S2) | 125.21 | 129.09 | 125.70 | 125.48 | |
| Support 3 (S3) | 121.12 | 125.21 | 124.64 | ||
| Support 4 (S4) | 122.10 |
